Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cabaletta Bio, Inc. (CABA)

11.86   1.41 (13.49%) 01-27 16:00
Open: 11.32 Pre. Close: 10.45
High: 12.1864 Low: 10.86
Volume: 1,165,792 Market Cap: 346(M)

Technical analysis

as of: 2023-01-27 4:43:10 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 14.23     One year: 16.62
Support: Support1: 9.11    Support2: 7.21
Resistance: Resistance1: 12.18    Resistance2: 14.23
Pivot: 10.34
Moving Average: MA(5): 11.23     MA(20): 10.19
MA(100): 4.29     MA(250): 2.69
MACD: MACD(12,26): 1.1     Signal(9): 1.1
Stochastic oscillator: %K(14,3): 76     %D(3): 78.8
RSI: RSI(14): 64.6
52-week: High: 12.18  Low: 0.58
Average Vol(K): 3-Month: 930 (K)  10-Days: 917 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CABA ] has closed below upper band by 9.0%. Bollinger Bands are 62.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.19 - 12.25 12.25 - 12.31
Low: 10.73 - 10.79 10.79 - 10.85
Close: 11.76 - 11.86 11.86 - 11.96

Company Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Sat, 28 Jan 2023
Cabaletta Bio (NASDAQ:CABA) Upgraded at Morgan Stanley - MarketBeat

Fri, 27 Jan 2023
The Horses Stood Like Men - Artsy

Fri, 27 Jan 2023
CABA stock jumps as Morgan Stanley upgrades on new CAR-T ... - Seeking Alpha

Fri, 27 Jan 2023
Morgan Stanley Upgrades Cabaletta Bio to Overweight From Equal Weight, $16 Price Target - Marketscreener.com

Wed, 25 Jan 2023
Stocks Off Session Lows Wednesday Ahead of Key Earnings Reports - InvestorsObserver

Fri, 20 Jan 2023
Gutierrez leads the Cuban American Bar Association - The Florida Bar

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 29 (M)
Shares Float 15 (M)
% Held by Insiders 11.3 (%)
% Held by Institutions 53 (%)
Shares Short 3,540 (K)
Shares Short P.Month 3,450 (K)

Stock Financials

EPS -1.85
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.96
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -30.2
Return on Equity (ttm) -50.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.74
Qtrly Earnings Growth 0
Operating Cash Flow -45 (M)
Levered Free Cash Flow -28 (M)

Stock Valuations

PE Ratio -6.45
PEG Ratio 0
Price to Book value 4
Price to Sales 0
Price to Cash Flow -7.73

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.